<DOC>
	<DOCNO>NCT00129558</DOCNO>
	<brief_summary>This Phase I/II , multi-centered , non-randomized , trial design determine safe dose PT-523 subject , make preliminary evaluation activity PT-523 therapy subject refractory leukemia .</brief_summary>
	<brief_title>A Study Evaluate PT-523 Patients With Refractory Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>Relapsed/refractory leukemia include acute nonlymphocytic leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , chronic lymphocytic leukemia ( CLL ) , chronic myelogenous leukemia blastic phase ( CMLBP ) standard therapy anticipate result durable remission ; poorrisk myelodysplasia ( MDS ) patient include refractory anemia excess blast ( RAEB ) excess blast transformation ( RAEBT ) chronic myelomonocytic leukemia ( CMML ) either relapsed/refractory refuse/are eligible frontline therapy . Only patient refractory ALL CML lymphoid blastic phase eligible phase II . ECOG performance status 0 2 . Adequate organ function bone marrow reserve . At least 4 week must elapse time major surgery . Use appropriate contraceptive method . Signed patient inform consent . Known human immunodeficiency virus ( HIV ) . Active heart disease include myocardial infarction within previous 3 month , symptomatic coronary artery disease , arrhythmias control medication , uncontrolled congestive heart failure . Patients receive standard investigational treatment leukemia corticosteriods , hydroxyurea , 6mercaptopurine . Any medical condition , opinion investigator , place patient unacceptably high risk toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>